Journey West: How One Small Chinese Firm Is Taking On The World

Global Place For Affordable AMD Option?

 
• By Brian Yang

When it kicked off a pivotal study in 32 countries, a small Chengdu-based company stepped into unknown waters littered with challenges, ranging from lack of expertise to limited enthusiasm for a made in China new drug, from controls over foreign currency outflows to vetting investigators in foreign lands. But a strong early performance at home has given Kanghong confidence to take on big pharma and the world.

KANGHONG VP SHU CHEN TALKS ABOUT THE CONBERCEPT GLOBAL PIII STUDY
KANGHONG VP SHU CHEN DISCUSSES CONBERCEPT GLOBAL STUDY AT CPhI China On 16 DEC 2020 • Source: Brian Yang

2016 marked a new chapter for Chengdu Kanghong Biotech Co., Ltd. That was when the China-based drug maker received approval from the US Food and Drug Administration to start a global study for its innovative new drug conbercept (KH902).

A vascular endothelial growth factor antagonist, conbercept was discovered by Kanghong and obtained its first approval from the China State...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?